NEXGEL, INC.

NEXGEL, INC.NXGLEarnings & Financial Report

Nasdaq · Health Care · Surgical & Medical Instruments & Apparatus

NEXGEL, INC. is a specialty consumer healthcare and medical technology firm that develops, manufactures and distributes ultra-gentle, irritation-free hydrogel products. Its offerings span over-the-counter skincare remedies, wound care solutions, and topical drug delivery platforms, serving consumer, clinical and pharmaceutical partner segments primarily across North America, with growing global distribution channels.

Revenue

$2.9M

Gross Profit

$1.3M

Operating Profit

$-636.0K

Net Profit

$-665.0K

Gross Margin

43.6%

Operating Margin

-22.1%

Net Margin

-23.1%

YoY Growth

100.3%

EPS

$-0.09

NEXGEL, INC. Q2 FY2025 Financial Summary

NEXGEL, INC. reported revenue of $2.9M (up 100.3% YoY) for Q2 FY2025, with a net profit of $-665.0K (up 24.9% YoY) (-23.1% margin). Cost of goods sold was $1.6M, operating expenses totaled $1.9M.

Key Financial Metrics

Total Revenue$2.9M
Net Profit$-665.0K
Gross Margin43.6%
Operating Margin-22.1%
Report PeriodQ2 FY2025

Revenue Breakdown

NEXGEL, INC. Q2 FY2025 revenue of $2.9M breaks down across 2 segments, led by Branded Consumer Products at $1.9M (65.3% of total).

SegmentRevenue% of Total
Branded Consumer Products$1.9M65.3%
Other$1.0M34.7%

NEXGEL, INC. Revenue by Segment — Quarterly Trend

NEXGEL, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Branded Consumer Products and Other) has evolved quarter over quarter.

SegmentQ4 FY2025Q3 FY2025Q2 FY2025Q1 FY2025
Branded Consumer Products$1.9M$1.9M
Other$1.0M$1.0M

NEXGEL, INC. Annual Revenue by Year

NEXGEL, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $11.4M).

YearAnnual Revenue
2025$11.4M
2024$8.7M
2023$4.1M
2022$2.0M

NEXGEL, INC. Quarterly Revenue & Net Profit History

NEXGEL, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q4 FY2025$2.8M-8.1%$-970.0K-34.7%
Q3 FY2025$2.9M-0.2%$-653.0K-22.3%
Q2 FY2025$2.9M+100.3%$-665.0K-23.1%
Q1 FY2025$2.8M+121.6%$-712.0K-25.4%
Q4 FY2024$3.0M+181.4%$-850.0K-27.9%
Q3 FY2024$2.9M+140.8%$-693.0K-23.6%
Q2 FY2024$1.4M+23.4%$-885.0K-61.5%
Q1 FY2024$1.3M+104.2%$-853.0K-67.4%

Income Statement

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Revenue$1.3M$1.4M$2.9M$3.0M$2.8M$2.9M$2.9M$2.8M
YoY Growth104.2%23.4%140.8%181.4%121.6%100.3%-0.2%-8.1%

Balance Sheet

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Assets$10.4M$9.8M$10.6M$11.0M$10.4M$9.7M$11.6M$10.5M
Liabilities$5.2M$5.2M$5.6M$4.9M$4.9M$4.7M$6.0M$5.6M
Equity$4.8M$4.2M$4.7M$5.8M$5.2M$4.7M$5.2M$4.5M

Cash Flow

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Operating CF$-1.1M$-700000$-1.2M$-859000$-400000$-407000$-785000$281000